CellSpring’s system, the 3D Bloom® Biopolymer Platform, enables "stop/go" decisions for preclinical candidates, according to Plasticell, which added that 3D cell cultures more closely resemble natural tissues when compared to conventional 2D cultures grown on flat dishes.
Additionally, the company said 3D tissues have more accurate biological responses to drug treatment.
As per the new collaboration, the companies will develop tissue models using 3D Bloom Biopolymer seeded with hMSCs, which are differentiated to bone, cartilage, and brown/white fat tissue in collaboration with Plasticell’s proprietary Combinatorial Cell Culture™ (CombiCult®) platform.
Aaron Chuang, Plasticell chief scientific officer, told Outsourcing-Pharma.com that the collaboration aims to “demonstrate the efficiency of Plasticell media in creating 3-dimensional cell cultures suitable for drug screening.”
“We aim to achieve the establishment of protocols to consistently generate bone and fat cells in 3-dimensional cultures for drug screening,” he added.
Chuang said the next steps moving forward will be joint publication and potential deployment of Plasticell media in CellSpring assays, adding that preliminary data demonstrates positive outcomes.